Join us for AltruBio’s R&D Update, where the company will provide an overview of its immune checkpoint enhancers which downregulate chronically activated T-cells by inhibiting T-cell effector function, promoting T-cell exhaustion and apoptosis. The management team will provide an overview of clinical proof of concept data across 4 indications. The development plans for next gen immune checkpoint enhancer, ALTB-268, with increased potency for subcutaneous administration in ulcerative colitis patients will also be discussed.

The update will feature Dr.  Sameem Abedin, MD (Medical College of Wisconsin) who will discuss the current treatment landscape and unmet medical needs for patients suffering from treatment refractory acute GVHD, as well as AltruBio’s most recent Phase 1b trial result with ALTB-168 in this patient population.

A live Q&A session will follow the formal presentations.